Invistics
Controlled Substance Compliance
Track controlled substances across the entire organization, from active pharmaceutical ingredients and reference standards, through the shipment of finished drug products to your customer, including R&D, analytical labs, samples, and the destruction of waste by reverse distributors.
Why Invistics?
To streamline controlled substance inventory management and comply with DEA regulations, pharmaceutical companies, researchers, and labs need accurate and “readily retrievable” records. With multiple registrations, sites, and locations to track, end-to-end visibility is crucial.
Flowlytics from Invistics helps pharmaceutical companies track controlled substances and comply with DEA reporting requirements. Track and report on DEA quotas, gain inventory visibility across the entire enterprise, and ensure controlled substance records are accurate with our secure cloud-based platform.
Reduce the risk of DEA audit findings, fines and letters of admonition by ensuring controlled substance records are accurate and readily retrievable.
Ensure all departments comply with DEA regulations, across multiple on-site DEA Registrations, from receipt all the way through to wasting.
Eliminate headaches and errors caused when controlled substances are tracked on paper, especially research, development, and analytics testing samples.
Improve the speed and accuracy of DEA reporting by converting paper records to electronic data, and by automating the flow of data from disparate systems into a single, centralized dashboard.
July 8, 2020
See how Invistics can help streamline your year-end reporting for Controlled Substance registrations, a typically slow and cumbersome process.
June 5, 2020
Learn how integrating data systems can streamline DEA reporting and allow proactive inventory management with an enterprise-wide view.
Latest Blog Posts
Pharmaceutical companies face unique challenges that add complexity for management. Learn about “pain” points for managing a successful supply chain.
Fourth in a series of blog posts documenting the journey of a large electric utility optimizing its extensive inventory of measuring and test equipment (M&TE).
Third in a series of blog posts documenting the journey of a large electric utility optimizing its extensive inventory of measuring and test equipment (M&TE).
Monitor location and quantity of controlled substances in real-time, with printable reports and accurate inventories for when the DEA calls.
The DEA decreased the number of opioids that may be manufactured in 2017. What does this mean for companies who manufacture controlled substances?
First in a series of blog posts documenting the journey of a large electric utility optimizing its extensive inventory of measuring and test equipment (M&TE).
Invistics CEO & Founder Tom Knight presented at the 2016 NCSLI Conference on how to use LEAN methods to improve efficiency and reduce waste in labs.
Fourth and last in a series of blog posts detailing how Invistics can help prevent controlled substance diversion.
Third in a blog series on preventing controlled substance diversion. The opioid crisis really hits home because it’s occurring right in our backyard: Atlanta.
Second in a blog series on preventing controlled substance diversion – the opioid epidemic has had devastating impact on children with addicted guardians.
First in a blog series on what we’ve learned preventing controlled substance diversion, and why Invistics is joining the fight against the opioid epidemic.
Learn what others in the Pharma Industry are doing to achieve best-in-class manufacturing operations using Lean Six Sigma methodology.